The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of updates to the pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions (eg, diabetes, chronic heart disease, chronic lung disease, or chronic liver disease, HIV) or other disease risk factors (eg, smoking, alcoholism).
For these patients, vaccination with a pneumococcal conjugate vaccine is recommended, either 20-valent pneumococcal conjugate vaccine (PCV20; Prevnar 20) or 15-valent pneumococcal conjugate vaccine (PCV15; Vaxneuvance). If PCV15 is used, this should be followed by a dose of PPSV23 (Pneumovax 23). The update applies to patients who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
Following review by the CDC director and the US Department of Health and Human Services, the final recommendations will be published in the Morbidity and Mortality Weekly Report.
The Food and Drug Administration (FDA) granted accelerated approval to Prevnar 20 in June 2021 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.
Vaxneuvance was subsequently approved in July 2021 for the prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.
- Advisory committee on immunization practices votes to recommend routine use of Pfizer’s Prevnar 20™ (pneumococcal 20-valent conjugate vaccine) in adults. News release. Pfizer Inc. October 20, 2021. https://www.businesswire.com/news/home/20211020006069/en/Advisory-Committee-on-Immunization-Practices-Votes-to-Recommend-Routine-Use-of-Pfizer%E2%80%99s-PREVNAR-20%E2%84%A2-Pneumococcal-20-valent-Conjugate-Vaccine-in-Adults.
- CDC ACIP unanimously votes to provisionally recommend Merck’s Vaxneuvance™ (pneumococcal 15-valent conjugate vaccine) in Series with Pneumovax® 23 (pneumococcal vaccine polyvalent) as an option for pneumococcal vaccination in appropriate Adults. News release. October 20, 2021. https://www.merck.com/news/cdc-acip-unanimously-votes-to-provisionally-recommend-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-series-with-pneumovax-23-pneumococcal-vaccine-polyvalen/.
This article originally appeared on MPR
Business News Governmental News Finance News